8-K: Phathom Pharma Q1 2026 Results: Revenue Surges, Profitability Ahead

Phathom Pharmaceuticals reported a 104% year-over-year increase in Q1 2026 net revenues to $58.3 million, while reducing operating expenses and maintaining full-year guidance with expected operating profitability in Q3 2026.

Summary

• Phathom Pharmaceuticals announced its first quarter 2026 financial results, reporting net revenues of $58.3 million, a significant 104% increase compared to $28.5 million in the first quarter of 2025.
• Total VOQUEZNA prescriptions filled to date reached approximately 1.35 million, with 268,000 prescriptions filled in Q1 2026, a 115% increase year-over-year.
• Operating expenses for Q1 2026 were $61.8 million, a substantial decrease from $103.7 million in Q1 2025, reflecting expense discipline and a 43% reduction in cash operating expenses year-over-year.
• The company maintained its full-year 2026 guidance, projecting net revenues between $320-$345 million and expecting operating profitability to begin in the third quarter of 2026 and continue for the full year.
• The Phase 2 pHalcon-EoE-201 trial for VOQUEZNA in eosinophilic esophagitis (EoE) is enrolling ahead of schedule, with topline results now anticipated in late Q4 2026 or early Q1 2027.
• As of March 31, 2026, Phathom had $180.9 million in cash and cash equivalents, and the company believes its current cash and anticipated future cash flow are sufficient to fund operations and meet debt obligations without needing additional capital raises.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and clear progress towards profitability, despite a slight miss on internal Q1 expectations and a continued net loss.

Positives

• Net revenues for Q1 2026 reached $58.3 million, a 104% increase year-over-year, driven by commercial strategy execution.
• Total VOQUEZNA prescriptions filled increased by 115% year-over-year in Q1 2026, reaching 268,000.
• Operating expenses decreased by $41.9 million year-over-year to $61.8 million in Q1 2026, with cash operating expenses down approximately 43%.
• Full-year 2026 net revenue guidance is maintained at $320-$345 million.
• Operating profitability is expected to commence in Q3 2026 and continue for the full year 2026.
• Cash and cash equivalents stood at $180.9 million as of March 31, 2026, providing a strong liquidity position.
• The EoE clinical trial is enrolling ahead of schedule, with results expected in late Q4 2026 or early Q1 2027.

Negatives

• First quarter results were slightly below internal expectations due to seasonal health plan access dynamics.
• Despite revenue growth, the company reported a net loss of $30.4 million for Q1 2026.
• Total liabilities were $642.1 million as of March 31, 2026, significantly exceeding total assets of $305.1 million, resulting in a substantial stockholders deficit of $337.0 million.

Risks

• The market opportunity for VOQUEZNA may be significantly smaller than anticipated.
• Market acceptance by healthcare professionals, patients, and payors may be lower than expected.
• Potential for coverage, reimbursement, or market access issues impacting commercialization efforts.
• The unmet need for new treatment options in GERD might not be as high as projected.
• Estimates of patient numbers and market size may prove inaccurate.
• Potential for generic competition sooner than anticipated due to patent or regulatory exclusivity challenges.
• Risk of adverse side effects or inadequate efficacy impacting market acceptance or leading to recalls.
• Dependence on third parties for commercialization, manufacturing, and clinical testing.

Future Outlook

Phathom is maintaining its full-year 2026 guidance, projecting net revenues between $320-$345 million. The company anticipates achieving operating profitability starting in the third quarter of 2026 and for the full year 2026, with cash flow positivity expected in 2027. The Phase 2 EoE trial is expected to report topline results in late Q4 2026 or early Q1 2027.

Management Comments

• "In the first quarter, we more than doubled revenue compared to the prior year Q1. We have implemented our pivot to GI and the associated sales force expansion."
• "We believe there is a path to $1 billion annual revenue in gastroenterology prescriptions, and we are encouraged by the strength of our new-to-brand prescription momentum."
• "While the first quarter reflected seasonal health plan access dynamics and was a bit light to internal expectations, we have seen a return to growth in late March and early April."
• "Our first quarter results demonstrate strong year-over-year revenue growth and continued execution against our plan, with net revenues of $58.3 million and net cash usage of approximately $15 million."
• "We maintained disciplined operations, reducing year-over-year cash operating expenses by more than 40%, while continuing to invest in our commercial organization and clinical pipeline."
• "With a strong balance sheet, an improved capital structure, and prescription trends strengthening as we enter the second quarter, we are maintaining our full year 2026 guidance and we believe we are on track to achieve operating profitability beginning in the third quarter and for the full year 2026 and reach cash flow positivity in 2027."

Industry Context

StockSavvy.ai notes that Phathom Pharmaceuticals' Q1 2026 results reflect strong commercial execution in the competitive biopharmaceutical market, particularly in the gastrointestinal disease segment. The significant year-over-year revenue growth and focus on expense discipline align with industry trends of prioritizing sustainable growth and operational efficiency.

Comparison to Industry Standards

• The 104% year-over-year revenue growth in Q1 2026 for Phathom Pharmaceuticals significantly outpaces the typical growth rates seen in established pharmaceutical companies, which often range from single digits to low double digits.
• The reduction in operating expenses by over 40% year-over-year demonstrates a strong focus on cost management, which is a critical factor for biotechs aiming for profitability, especially when compared to companies that may maintain higher R&D or SG&A spending relative to revenue.
• The projected operating profitability in Q3 2026 and for the full year 2026, following a period of significant investment, is a key milestone. Many biopharma companies take longer to reach this stage, making Phathom's timeline aggressive.
• The net cash usage of ~$15 million in Q1 2026, while substantial, is considerably lower than the net loss of $30.4 million, indicating effective management of cash burn relative to the overall financial performance.

Stakeholder Impact

• Shareholders: Potential for increased value as the company moves towards profitability and strengthens its financial position.
• Employees: Continued investment in the commercial organization and clinical pipeline suggests ongoing employment opportunities and focus on growth.
• Customers (Patients): Access to VOQUEZNA for GI diseases and H. pylori infections is being expanded through commercial efforts.
• Suppliers/Partners: Continued business operations and potential for increased demand for services and products related to VOQUEZNA commercialization and development.

Next Steps

• Continue commercialization efforts for VOQUEZNA.
• Monitor prescription trends and revenue growth entering the second quarter.
• Achieve operating profitability beginning in Q3 2026.
• Reach cash flow positivity in 2027.
• Report topline results from the Phase 2 pHalcon-EoE-201 trial in late Q4 2026 or early Q1 2027.

Key Dates

Recommendation

The company shows strong revenue growth and a clear path to profitability, but the continued net loss, significant liabilities, and the slight miss on internal Q1 expectations warrant a cautious 'hold' rating. Investors should monitor the achievement of profitability targets and prescription growth momentum.

Keywords

Phathom Pharmaceuticals, VOQUEZNA, Q1 2026 Earnings, Gastrointestinal Diseases, Biopharmaceutical, Financial Results, Eosinophilic Esophagitis, Prescription Growth